Intellia Therapeutics, Inc. (NTLA) has put up a dismal performance in 2024. Shares of the company have plunged 60.4% compared with the industry’s decline of 13.7%. The deterioration was more pronounced in the past five months. The stock has also underperformed the sector and the S&P 500 Index during this time frame.Intellia is a leading clinical-stage gene editing company focused on developing innovative CRISPR-based therapies. While these innovative therapies have been in the spotlight following the FDA ap ...